Armistice Capital LLC acquired a new position in shares of Biopharmx Corp (NYSEAMERICAN:BPMX) during the 4th quarter, HoldingsChannel.com reports. The firm acquired 3,470,000 shares of the biotechnology company’s stock, valued at approximately $382,000.
In related news, major shareholder Vivo Capital Viii, Llc sold 2,000,000 shares of the firm’s stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $0.36, for a total value of $720,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Biopharmx Corp (NYSEAMERICAN:BPMX) opened at $0.33 on Friday. Biopharmx Corp has a 12-month low of $0.10 and a 12-month high of $0.90. The company has a market capitalization of $37.11, a price-to-earnings ratio of -1.22 and a beta of 0.43.
Separately, Maxim Group reiterated a “buy” rating and set a $1.50 price objective on shares of Biopharmx in a research report on Friday, December 8th.
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Want to see what other hedge funds are holding BPMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biopharmx Corp (NYSEAMERICAN:BPMX).
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.